Innovative Neuroscience Focus BrainXell specializes in high-purity, iPSC-derived neurons for drug discovery and neuroscience research, positioning it as a key partner for biotech and pharmaceutical companies seeking advanced neurobiological tools.

Expanding Therapeutic Pipeline With a lead program, BXT-110, progressing toward IND-enabling trials for Parkinson’s disease and a second program for spinal cord injury, BrainXell presents opportunities for collaboration in neurology drug development.

Recent Industry Engagements Participation in notable events like the Society for Neuroscience Annual Meeting and SLAS Conference highlights BrainXell’s active presence in key research communities, ideal for forging connections with research institutions and early adopters.

Strategic Collaborations Partnerships with in vitro model developers like Xona Microfluidics indicate a focus on advancing disease modeling, providing potential avenues for joint ventures or supply agreements to enhance research tools.

Financial Growth Opportunities With revenues estimated between 10M-25M and recent funding of 13M, BrainXell is positioned for capacity expansion and technology development, offering a range of sales opportunities in research reagents, development services, and therapeutic collaborations.